[边缘区淋巴瘤诊治现状分析与思考]。

Q3 Medicine
W Z Yan, X X Xiang, G H Cui, Y Hu, B Lyu, X Zhang, H L Peng
{"title":"[边缘区淋巴瘤诊治现状分析与思考]。","authors":"W Z Yan, X X Xiang, G H Cui, Y Hu, B Lyu, X Zhang, H L Peng","doi":"10.3760/cma.j.cn112137-20241012-02311","DOIUrl":null,"url":null,"abstract":"<p><p>The current study aimed to understand the current status and problems of marginal zone lymphoma (MZL) in the diagnosis and treatment of hospitals at all levels in China. A multi-center questionnaire survey was conducted in a number of medical institutions across the country. A combination of online questionnaire survey and face-to-face interview was adopted. (1)Pathologists paid more attention than clinicians to distinguish MALT from chronic inflammation (86.3% vs 32.1%, <i>P<</i>0.01) and plasma cell tumor (51.8% vs 23.1%, <i>P<</i>0.01). A total of 21% pathologists never performed B-cell gene rearrangement, 67.6% of clinicians and 69.0% of pathologists would not recommend splenic puncture to diagnose SMZL.(2)In terms of treatment indications, 40.0% of clinicians mistakenly believed that stage Ⅲ-Ⅳ was also a treatment indication. Seventy percent of clinicians reported confusion about treatment indications. (3) In staging and efficacy evaluation, 63.3% of physicians performed PET-CT testing for patients, mainly for resolving clinical staging (89.0%), identifying histologically transformation (79.6%), and determining the site of radiotherapy or biopsy (66.2%). (4) In terms of treatment choice, only 32.2% of patients with indications were recommended for radiotherapy, and the proportion of hematologists choosing radiotherapy was significantly lower than that of oncologists (42.6% vs 71.7%, <i>P</i><0.01); In the anti-HP indications, 53.1% of physicians will perform anti-HP therapy regardless of Hp positive or not; For advanced MZL, first-line immunochemotherapy was selected by 62.7% of clinicians, compared with 37.3% for targeted therapy. (5)15.3% of clinicians believed that the current prognostic evaluation system could not guide the selection of treatment options after initial treatment and recurrence. At present, there are still some cognitive deviations in the disease cognition and treatment indication of MZL among clinicians at all levels of hospitals in China. Likewise, there are still many unmet needs in MZL staging, efficacy evaluation, treatment selection and prognosis evaluation.</p>","PeriodicalId":24023,"journal":{"name":"Zhonghua yi xue za zhi","volume":"104 48","pages":"4360-4365"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Analysis and reflections on the current status of diagnosis and treatment of marginal zone lymphoma].\",\"authors\":\"W Z Yan, X X Xiang, G H Cui, Y Hu, B Lyu, X Zhang, H L Peng\",\"doi\":\"10.3760/cma.j.cn112137-20241012-02311\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The current study aimed to understand the current status and problems of marginal zone lymphoma (MZL) in the diagnosis and treatment of hospitals at all levels in China. A multi-center questionnaire survey was conducted in a number of medical institutions across the country. A combination of online questionnaire survey and face-to-face interview was adopted. (1)Pathologists paid more attention than clinicians to distinguish MALT from chronic inflammation (86.3% vs 32.1%, <i>P<</i>0.01) and plasma cell tumor (51.8% vs 23.1%, <i>P<</i>0.01). A total of 21% pathologists never performed B-cell gene rearrangement, 67.6% of clinicians and 69.0% of pathologists would not recommend splenic puncture to diagnose SMZL.(2)In terms of treatment indications, 40.0% of clinicians mistakenly believed that stage Ⅲ-Ⅳ was also a treatment indication. Seventy percent of clinicians reported confusion about treatment indications. (3) In staging and efficacy evaluation, 63.3% of physicians performed PET-CT testing for patients, mainly for resolving clinical staging (89.0%), identifying histologically transformation (79.6%), and determining the site of radiotherapy or biopsy (66.2%). (4) In terms of treatment choice, only 32.2% of patients with indications were recommended for radiotherapy, and the proportion of hematologists choosing radiotherapy was significantly lower than that of oncologists (42.6% vs 71.7%, <i>P</i><0.01); In the anti-HP indications, 53.1% of physicians will perform anti-HP therapy regardless of Hp positive or not; For advanced MZL, first-line immunochemotherapy was selected by 62.7% of clinicians, compared with 37.3% for targeted therapy. (5)15.3% of clinicians believed that the current prognostic evaluation system could not guide the selection of treatment options after initial treatment and recurrence. At present, there are still some cognitive deviations in the disease cognition and treatment indication of MZL among clinicians at all levels of hospitals in China. Likewise, there are still many unmet needs in MZL staging, efficacy evaluation, treatment selection and prognosis evaluation.</p>\",\"PeriodicalId\":24023,\"journal\":{\"name\":\"Zhonghua yi xue za zhi\",\"volume\":\"104 48\",\"pages\":\"4360-4365\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhonghua yi xue za zhi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn112137-20241012-02311\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua yi xue za zhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112137-20241012-02311","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Analysis and reflections on the current status of diagnosis and treatment of marginal zone lymphoma].

The current study aimed to understand the current status and problems of marginal zone lymphoma (MZL) in the diagnosis and treatment of hospitals at all levels in China. A multi-center questionnaire survey was conducted in a number of medical institutions across the country. A combination of online questionnaire survey and face-to-face interview was adopted. (1)Pathologists paid more attention than clinicians to distinguish MALT from chronic inflammation (86.3% vs 32.1%, P<0.01) and plasma cell tumor (51.8% vs 23.1%, P<0.01). A total of 21% pathologists never performed B-cell gene rearrangement, 67.6% of clinicians and 69.0% of pathologists would not recommend splenic puncture to diagnose SMZL.(2)In terms of treatment indications, 40.0% of clinicians mistakenly believed that stage Ⅲ-Ⅳ was also a treatment indication. Seventy percent of clinicians reported confusion about treatment indications. (3) In staging and efficacy evaluation, 63.3% of physicians performed PET-CT testing for patients, mainly for resolving clinical staging (89.0%), identifying histologically transformation (79.6%), and determining the site of radiotherapy or biopsy (66.2%). (4) In terms of treatment choice, only 32.2% of patients with indications were recommended for radiotherapy, and the proportion of hematologists choosing radiotherapy was significantly lower than that of oncologists (42.6% vs 71.7%, P<0.01); In the anti-HP indications, 53.1% of physicians will perform anti-HP therapy regardless of Hp positive or not; For advanced MZL, first-line immunochemotherapy was selected by 62.7% of clinicians, compared with 37.3% for targeted therapy. (5)15.3% of clinicians believed that the current prognostic evaluation system could not guide the selection of treatment options after initial treatment and recurrence. At present, there are still some cognitive deviations in the disease cognition and treatment indication of MZL among clinicians at all levels of hospitals in China. Likewise, there are still many unmet needs in MZL staging, efficacy evaluation, treatment selection and prognosis evaluation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Zhonghua yi xue za zhi
Zhonghua yi xue za zhi Medicine-Medicine (all)
CiteScore
0.80
自引率
0.00%
发文量
400
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信